Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Non-Hodgkin × ofatumumab × Clear all

Phase

Phase 2 8 Phase 1/2 3 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6 Neoplasms 3 Leukemia, B-Cell 3 Recurrence 2 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia 1 Bronchiolitis Obliterans Syndrome 1 Autoimmune Diseases of the Nervous System 1 Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1

Interventions

Rituximab 53 Cyclophosphamide 32 Vincristine 24 Doxorubicin 22 Prednisone 20 Bendamustine Hydrochloride 16 Etoposide 13 Radiotherapy 11 Cytarabine 9 ibrutinib 6 fludarabine 6 VAP-cyclo protocol 6 Prednisolone 6 Peripheral Blood Stem Cell Transplantation 6 Granulocyte Colony-Stimulating Factor 6 Gemcitabine 6 Filgrastim 6 pirtobrutinib 5 ibritumomab tiuxetan 5 Methotrexate 5 Melphalan 5 Lenalidomide 5 pixantrone 4 Mitoxantrone 4 Epoetin Alfa 4 Cyclosporine 4 Carmustine 4 Bleomycin 4 venetoclax 3 tositumomab I-131 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01200589 2018-05-16

HOMER

Novartis

Phase 3 Terminated

438 enrolled 14 charts

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡